Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study)

被引：0
作者：
Takao Takahashi
Yasunori Emi
Eiji Oki
Kazuma Kobayashi
Akihito Tsuji
Mototsugu Shimokawa
Takaho Tanaka
Yoshito Akagi
Yutaka Ogata
Hideo Baba
Kazuhiro Yoshida
Shoji Natsugoe
Yoshihiko Maehara
机构：
[1] Gifu University Graduate School of Medicine,Department of Surgical Oncology
[2] Saiseikai Fukuoka General Hospital,Department of Surgery
[3] Kyushu University,Department of Surgery and Science, Graduate School of Medical Sciences
[4] Nagasaki University Graduate School of Biomedical Sciences,Department of Surgery
[5] Kobe City Medical Center General Hospital,Department of Medical Oncology
[6] National Kyushu Cancer Center Clinical Research Institute,Department of Cancer Information Research
[7] Social Insurance Tagawa Hospital,Department of Surgery
[8] Kurume University School of Medicine,Department of Surgery
[9] Kurume University Medical Center,Department of Surgery
[10] Kumamoto University,Department of Gastroenterological Surgery, Graduate School of Medical Sciences
[11] Kagoshima University Graduate School of Medical and Dental Sciences,Department of Digestive Surgery, Breast and Thyroid Surgery
来源：
Cancer Chemotherapy and Pharmacology | 2016年 / 78卷
关键词：
Cetuximab; S-1; Third-line treatment; Unresectable metastatic colorectal cancer; KRAS; BRAF;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：585 / 593
页数：8
相关论文
共 265 条
[1]  
Kopetz S(2009)Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy J Clin Oncol 27 3677-3683
[2]  
Chang GJ(2001)The EGFR as a target for anticancer therapy-focus on cetuximab Eur J Cancer 37 S16-S22
[3]  
Overman MJ(2001)A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor Clin Cancer Res 7 2958-2970
[4]  
Eng C(2007)Cetuximab for the treatment of colorectal cancer N Engl J Med 357 2040-2048
[5]  
Sargent DJ(2004)Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 337-345
[6]  
Larson DW(2009)Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 1408-1417
[7]  
Grothey A(2009)Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 663-671
[8]  
Vauthey JN(2008)K-ras Mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 1757-1765
[9]  
Nagorney DM(2012)Combination therapy using oral S-1 and targeted agents against human tumor xenografts in nude mice Exp Ther Med 3 755-762
[10]  
McWilliams RR(2000)Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice Cancer 89 74-82
12345678910